• |
Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022,
|
• |
Enrolled first patient in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy, and
|
• |
Decreased operating expenses 14% compared to the second quarter of 2021 to minimize cash utilization while continuing to fund key strategic initiatives.
|
• |
Webcast link for interested listeners:
|
o | https://edge.media-server.com/mmc/p/frxpm437 |
• |
Dial-in registration for sell-side research analysts:
|
o | https://register.vevent.com/register/BIea28b3e149034b04b99b65da059db74a |
June 30,
2022
|
December 31,
2021
| |||||||
ASSETS
|
(unaudited)
| |||||||
Current assets
| ||||||||
Cash and cash equivalents
|
$
|
15,345
|
$
|
24,205
| ||||
Accounts receivable
|
1,313
|
750
| ||||||
Inventories
|
3,010
|
2,843
| ||||||
Other current assets
|
252
|
328
| ||||||
Total current assets
|
19,920
|
28,126
| ||||||
Property, plant and equipment, net
|
1,063
|
1,188
| ||||||
Operating lease right-of-use asset
|
994
|
1,082
| ||||||
Other assets
|
21
|
21
| ||||||
TOTAL ASSETS
|
$
|
21,998
|
$
|
30,417
| ||||
LIABILITIES AND STOCKHOLDERS' EQUITY
| ||||||||
Current liabilities
| ||||||||
Accounts payable
|
$
|
1,550
|
$
|
1,414
| ||||
Accrued compensation
|
1,633
|
1,664
| ||||||
Current portion of operating lease liability
|
186
|
167
| ||||||
Current portion of finance lease liability
|
27
|
26
| ||||||
Other current liabilities
|
63
|
36
| ||||||
Total current liabilities
|
3,459
|
3,307
| ||||||
Operating lease liability
|
860
|
956
| ||||||
Finance lease liability
|
15
|
28
| ||||||
Other long-term liability
|
-
|
179
| ||||||
Total liabilities
|
4,334
|
4,470
| ||||||
Commitments and contingencies
| ||||||||
Stockholders' equity
| ||||||||
Series A junior participating preferred stock as of June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 30,000 shares, none outstanding
|
-
|
-
| ||||||
Series F convertible preferred stock as of both June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares
|
-
|
-
| ||||||
Preferred stock as of both June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding
|
-
|
-
| ||||||
Common stock as of June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 shares
|
1
|
1
| ||||||
Additional paid-in capital
|
279,350
|
278,873
| ||||||
Accumulated other comprehensive income:
| ||||||||
Foreign currency translation adjustment
|
(12
|
)
|
(11
|
)
| ||||
Accumulated deficit
|
(261,675
|
)
|
(252,916
|
)
| ||||
Total stockholders' equity
|
17,664
|
25,947
| ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
21,998
|
$
|
30,417
|
Three months ended
June 30,
|
Six months ended
June 30,
| |||||||||||||||
2022
|
2021
|
2022
|
2021
| |||||||||||||
Net sales
|
$
|
2,213
|
$
|
2,508
|
$
|
4,139
|
$
|
4,426
| ||||||||
Cost of goods sold
|
1,150
|
997
|
1,974
|
1,949
| ||||||||||||
Gross profit
|
1,063
|
1,511
|
2,165
|
2,477
| ||||||||||||
Operating expenses:
| ||||||||||||||||
Selling, general and administrative
|
4,257
|
5,063
|
8,669
|
10,300
| ||||||||||||
Research and development
|
1,107
|
1,174
|
2,213
|
2,121
| ||||||||||||
Total operating expenses
|
5,364
|
6,237
|
10,882
|
12,421
| ||||||||||||
Loss from operations
|
(4,301
|
)
|
(4,726
|
)
|
(8,717
|
)
|
(9,944
|
)
| ||||||||
Other income (expense), net
|
17
|
(2
|
)
|
(38
|
)
|
(3
|
)
| |||||||||
Loss before income taxes
|
(4,284
|
)
|
(4,728
|
)
|
(8,755
|
)
|
(9,947
|
)
| ||||||||
Income tax expense
|
(2
|
)
|
(3
|
)
|
(4
|
)
|
(5
|
)
| ||||||||
Net loss
|
$
|
(4,286
|
)
|
$
|
(4,731
|
)
|
$
|
(8,759
|
)
|
$
|
(9,952
|
)
| ||||
Basic and diluted loss per share
|
$
|
(0.41
|
)
|
$
|
(0.72
|
)
|
$
|
(0.83
|
)
|
$
|
(2.04
|
)
| ||||
Weighted average shares outstanding - basic and diluted
|
10,538
|
6,532
|
10,538
|
4,887
| ||||||||||||
Other comprehensive loss:
| ||||||||||||||||
Foreign currency translation adjustments
|
$
|
1
|
$
|
-
|
$
|
(1
|
)
|
$
|
(3
|
)
| ||||||
Total comprehensive loss
|
$
|
(4,285
|
)
|
$
|
(4,731
|
)
|
$
|
(8,760
|
)
|
$
|
(9,955
|
)
|
Six months ended
June 30,
| ||||||||
2022
|
2021
| |||||||
Operating Activities:
| ||||||||
Net loss
|
$
|
(8,759
|
)
|
$
|
(9,952
|
)
| ||
Adjustments to reconcile net loss to cash flows used in operating activities:
| ||||||||
Depreciation and amortization
|
206
|
256
| ||||||
Stock-based compensation expense, net
|
477
|
736
| ||||||
Changes in operating assets and liabilities:
| ||||||||
Accounts receivable
|
(563
|
)
|
(272
|
)
| ||||
Inventory
|
(167
|
)
|
122
| |||||
Other current assets
|
76
|
(176
|
)
| |||||
Other assets and liabilities
|
(152
|
)
|
9
| |||||
Accounts payable and accrued expenses
|
117
|
75
| ||||||
Net cash used in operating activities
|
(8,765
|
)
|
(9,202
|
)
| ||||
Investing Activities:
| ||||||||
Purchases of property and equipment
|
(81
|
)
|
(137
|
)
| ||||
Net cash used in investing activities
|
(81
|
)
|
(137
|
)
| ||||
Financing Activities:
| ||||||||
Proceeds from public stock offerings, net
|
-
|
18,896
| ||||||
Proceeds from warrant exercises
|
-
|
1
| ||||||
Payments on finance lease liability
|
(13
|
)
|
(14
|
)
| ||||
Net cash provided (used in) by financing activities
|
(13
|
)
|
18,883
| |||||
Effect of exchange rate changes on cash
|
(1
|
)
|
(3
|
)
| ||||
Net increase (decrease) in cash and cash equivalents
|
(8,860
|
)
|
9,541
| |||||
Cash and cash equivalents - beginning of period
|
24,205
|
14,437
| ||||||
Cash and cash equivalents - end of period
|
$
|
15,345
|
$
|
23,978
| ||||
Supplemental cash flow information
| ||||||||
Inventory transferred to property, plant and equipment
|
$
|
-
|
$
|
179
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nuwellis Inc. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 14:45:22 UTC.